Literature DB >> 25135435

Dosing and effectiveness of ketamine anesthesia for electroconvulsive therapy (ECT): a case series.

Ethan O Bryson1, Gabriella M Ahle2, Lauren S Liebman2, Amy S Aloysi3, Matthew F Majeske4, Kyle A Lapidus5, Charles H Kellner6.   

Abstract

OBJECTIVE: To provide additional data about the clinical efficacy and dosing range for ketamine used as the induction agent in electroconvulsive therapy (ECT).
METHOD: We reviewed the clinical data in our academic hospital ECT service over the last four years for patients who had received ketamine as the sole, or adjunctive, anesthesia induction agent. We extracted clinical data about antidepressant response as well as absolute and weight-based dosing for ketamine.
RESULTS: We found nine patients who were treated with ketamine as the anesthetic at some point during the course of their treatment (eight as the sole agent, one as adjunctive). The median induction dose for ketamine was 1.1 mg/kg. For most patients, there was demonstrable clinical benefit.
CONCLUSIONS: Ketamine has a role as an alternative induction anesthetic agent in ECT. Our case series adds to the literature on the concomitant use of ECT and ketamine. © The Royal Australian and New Zealand College of Psychiatrists 2014.

Entities:  

Keywords:  ECT; electroconvulsive therapy; ketamine

Mesh:

Substances:

Year:  2014        PMID: 25135435     DOI: 10.1177/1039856214545547

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  2 in total

1.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

2.  Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia.

Authors:  Suna Su Aksay; Jan Malte Bumb; Dmitry Remennik; Manfred Thiel; Laura Kranaster; Alexander Sartorius; Christoph Janke
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-23       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.